The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level
Open Access
- 1 November 2016
- journal article
- research article
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 15 (11) , 3348-3360
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (CA131582, CA009171, K99CA194318, CA010815)
- Ovarian Cancer Research Fund (Program Project)
This publication has 54 references indexed in Scilit:
- Insights into the regulation of protein abundance from proteomic and transcriptomic analysesNature Reviews Genetics, 2012
- Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate PathwayCell, 2012
- Regulation of HMG-CoA reductase in mammals and yeastProgress in Lipid Research, 2011
- Cholesterol-Dependent Degradation of Squalene Monooxygenase, a Control Point in Cholesterol Synthesis beyond HMG-CoA ReductaseCell Metabolism, 2011
- Andromeda: A Peptide Search Engine Integrated into the MaxQuant EnvironmentJournal of Proteome Research, 2011
- Systematic Discovery of Ectopic Pregnancy Serum Biomarkers Using 3-D Protein Profiling Coupled with Label-free QuantitationJournal of Proteome Research, 2010
- ARID1AMutations in Endometriosis-Associated Ovarian CarcinomasNew England Journal of Medicine, 2010
- The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer developmentTrends in Cell Biology, 2009
- MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantificationNature Biotechnology, 2008
- Regulation of the mevalonate pathwayNature, 1990